St. Jude Medical develops medical technology and services that focus on putting more control into the hands of those who treat cardiac, neurological and chronic pain patients worldwide. The company is dedicated to advancing the practice of medicine by reducing risk wherever possible and contributing to successful outcomes for every patient. Headquartered in St. Paul, Minn., St. Jude Medical employs more than 16,000 people worldwide and has four major focus areas that include: cardiac rhythm management, atrial fibrillation, cardiovascular and neuromodulation.
The St. Jude Medical product portfolio includes implantable cardioverter defibrillators (ICDs), cardiac resynchronization therapy (CRT) devices, pacemakers, electrophysiology catheters, mapping and visualization systems, vascular closure devices, structural heart products, spinal cord stimulation and deep brain stimulation devices.
Company Facts
| Headquarters |
St. Paul, Minnesota, USA |
| Stock Exchange |
New York Stock Exchange (NYSE) under "STJ" symbol |
| Founded |
1976 in St. Paul, Minnesota |
| 2010 Net Sales |
$5.165 billion |
| Global Reach |
St. Jude Medical has operations and manufacturing facilities worldwide, with products sold in more than 100 countries. |
| Employees |
More than 16,000 employees worldwide |
| Global Reach |
Products sold in more than 100 countries |
Foundation |
St. Jude Medical (SJM) Foundation, the philanthropic arm of St. Jude Medical, supports organizations whose missions are to promote health awareness and advance the state of medical knowledge through education, research and training. |
Highlights
- St. Jude Medical has significant programs in place that we expect to benefit our 2011 and 2012 margins and capture EPS (earnings per share) leverage while maintaining our investments in long-term growth drivers
- No. 436 on FORTUNE 500 List of Companies.
- EPS (GAAP) five-year compounded annual growth rate was 21.5% from 2005 through 2010.
- We plan to continue investing at least 12.5% of sales in R&D with a strong focus on continued investment in clinical trials for the benefit of our customers and the patients they serve. This level of investment will fund our robust growth program, which includes both short and long-term opportunities.
Growth at St. Jude Medical
St. Jude Medical is committed to continuous innovation and growth in its people, product portfolios and clinical research programs. The company sees growth opportunities in each of its technology platforms:
Atrial Fibrillation
St. Jude Medical is a pioneer and leader in the AF market, which is estimated to be about $2 billion in revenue size. The company offers the industry’s broadest product portfolio for the EP lab, aiding physicians in the diagnosis and treatment of cardiac arrhythmias. During 2010 the company launched its newest advanced catheter technologies, EnSite Contact™ and Therapy™ Cool Flex™ catheters, in Europe and will continue to roll out these technologies around the world during 2011. Through our recent acquisition of AGA Medical, the company also added a left atrial appendage (LAA) closure device for the treatment of AF. This technology currently is approved in Europe and is expected to receive pre-market approval in 2013.
Cardiac Rhythm Management
The worldwide CRM market is approximately $12 billion and St. Jude Medical is focused on gaining share in this market with several promising technologies. In 2010, St. Jude Medical launched in Europe the world’s first quadripolar CRT system, and plans to launch quadripolar technology in the U.S. mid-2011. The company also globally launched the Unify™ CRT-D and Fortify™ ICD in 2010, featuring the smallest device footprint available, without compromising on energy, longevity, safety or reliability.
Neuromodulation
St. Jude Medical participates in the $2 billion neuromodulation market. The company has received approvals for its deep brain stimulation systems in Europe and Australia, and continues to have the smallest, longest-lasting spinal cord stimulators for chronic pain and deep brain stimulators for Parkinson’s disease on the market. The company also has clinical research programs focused on potential indications for migraine, depression, Parkinson’s disease and numerous other disease states.
Cardiovascular
St. Jude Medical participates in segments of the vascular closure and structural heart markets totaling approximately $3 billion. We have strong franchises in FFR (Fractional Flow Reserve) measurement systems, OCT (Optical Coherence Tomography) intravascular imaging systems, vascular closure and heart valve repair. With our recent acquisition of AGA Medical, we are now the leader in the market for repairing atrial septal defects, ventricular septal defects, and other structural heart defects with minimally invasive catheter technology.
Performance and Progress
